Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when NTRA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsNatera expands Board to 11 members, appoints Eric Rubin as independent director
Filed April 1, 2026 · Period ending March 26, 2026 · ~1 min read
Key Changes
-
medium
Board expanded from 10 to 11 members and appointed Eric Rubin as Class I director effective March 26, 2026, with term expiring at 2028 annual meeting. Appointment followed recommendation from Nominating Committee.
Item 5.02 verify on EDGAR → -
low
Dr. Rubin qualified as independent director under SEC and Nasdaq standards and assigned to Nominating, Corporate Governance and Compliance Committee.
Item 5.02 verify on EDGAR → -
low
New director will receive standard non-employee director compensation with initial equity award vesting in three equal annual installments on March 26 of 2027, 2028, and 2029.
Item 5.02 verify on EDGAR →
Summary
Natera expanded its Board of Directors from ten to eleven members and appointed Eric Rubin as an independent director effective March 26, 2026. Dr. Rubin will serve as a Class I director with his initial term expiring at the 2028 annual stockholders meeting.
The Board determined he meets independence requirements under both SEC regulations and Nasdaq listing standards, and assigned him to the Nominating, Corporate Governance and Compliance Committee. For retail investors, this is a routine governance matter reflecting normal board evolution. Board expansion typically signals the company values additional expertise or perspectives as it grows. Dr.
Rubin's appointment to the governance committee suggests he brings relevant experience in board oversight and compliance matters. His compensation follows the standard structure for non-employee directors, with equity vesting over three years to align his interests with long-term shareholder value. Investors should watch for disclosure of Dr. Rubin's specific background and expertise in upcoming proxy materials, which will clarify what capabilities he brings to Natera's board during this growth phase.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 8, 2026 · How we verify